Gilead Sciences, Inc. (NASDAQ:GILD) announced a total of 96% of patients achieved sustained virologic response in pooled analysis of several Phase 2 and Phase 3 studies evaluating Harvoni for the treatment of chronic hepatitis C virus (HCV) infection. The study targeted patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals. Patients received Harvoni alone or with ribavirin (RBV) for 12 or 24 weeks.
The data will be presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases in Boston. Harvoni was approved by the U.S. Food and Drug Administration and Health Canada in October 2014 as a once-daily single tablet regimen for the treatment of chronic HCV genotype 1 infection in adults. Applications are pending in the European Union, Japan and New Zealand. Shares of Gilead Sciences, Inc. (NASDAQ:GILD) are trading within a 52-week range of $63.50 - $116.83.Click here for a free comprehensive Trend Analysis ReportSAGE Therapeutics Inc (NASDAQ:SAGE) reported a wider Q3 loss than a year ago on higher research and development costs as well as general and administrative costs. The biopharmaceutical company said the net loss attributable to shareholders widened to $9.9 million from $4.5 million while on a per-share basis it dropped to $0.50 per diluted share from $2.98 as the share count surged in the wake of its initial public offering in July. SAGE Therapeutics Inc (NASDAQ:SAGE) had no revenue in the quarter. No analyst estimates were available for comparison. The company recently met both the primary efficacy and safety endpoints it its Phase 1/2 clinical trial of SAGE-547 in patients with super-refractory status epilepticus."Based on the activity of SAGE-547 in this trial combined with the observed ability of SAGE-547 to halt status epilepticus in emergency-use cases, we are focusing our efforts on initiating our pivotal trial for treatment of this disorder in the first half of 2015, pending our discussions with the FDA," CEO Jeff Jonas said in a statement. "We are excited about the potential for SAGE-547, as well as our earlier-stage programs, to treat multiple orphan genetic epilepsies and other rare disorders for which there are few to no approved treatment options."Click here for a free comprehensive Trend Analysis ReportCST Brands Inc (NYSE:CST) reported net income that was significantly higher than the year prior while revenue declined. Net income was $63 million, or $0.83 per diluted share. Net income was $42 million, or $0.56 per diluted share, for the comparable period in 2013. Excluding these items, net income would have been $68 million, or $0.90 per diluted share, and $44 million, or $0.58 per diluted share, for the three month periods ended September 30, 2014 and 2013, respectively. Analyst estimates called for earnings of $0.57 per share. Operating revenue was $3.2 million, down from $3.3 million a year prior. The Street called for revenue of $3.3 billion. CST Brands Inc (NYSE:CST) trades in a 52-week range of $29.53 to $40.30.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
